Study #2022-0896
EON: A single-arm Phase II study of Etigilimab (OMP-313M32) in combination with checkpoint inhibition (Nivolumab) in patients with platinum-resistant, recurrent epithelial ovarian cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab, Etigilimab
Description
To learn if adding etigilimab to nivolumab therapy can help to control clear cell ovarian, fallopian tube, and primary peritoneal cancers that are resistant to platinum-based therapy
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer
Study phase:
Phase II
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-563-0193
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.